Artesunate Shows Promise as First Effective Treatment for Kidney Fibrosis
Anti-malarial drug artesunate significantly reduced kidney scarring in mice by restoring protective klotho protein and blocking fibrosis pathways.
Summary
Researchers tested artesunate, an anti-malarial drug, as a potential treatment for kidney fibrosis—the scarring that drives chronic kidney disease progression. Using a mouse model where kidney scarring was induced by blocking urine flow, they found artesunate significantly reduced fibrosis markers and restored protective proteins. The drug worked by blocking multiple harmful pathways while restoring klotho, an anti-aging protein that protects kidneys. Currently, no effective treatments exist to stop kidney fibrosis progression to end-stage kidney failure, making this a potentially important therapeutic breakthrough.
Detailed Summary
Chronic kidney disease affects millions globally and often progresses to kidney failure and premature death, with kidney fibrosis being the main driver regardless of the underlying cause. This scarring process involves excessive collagen buildup that irreversibly damages kidney function, yet no effective anti-fibrotic treatments currently exist to halt progression to end-stage kidney failure.
Researchers investigated artesunate, a derivative of artemisinin from Chinese herbal medicine and a first-line anti-malarial drug, for its potential to treat kidney fibrosis. They used a well-established mouse model called unilateral ureteral obstruction (UUO), where one ureter is surgically blocked to induce kidney scarring over 10 days. Male mice received either artesunate (100 mg/kg daily) or vehicle control via injection, with sham-operated controls undergoing surgery without ureter blockage.
Artesunate treatment dramatically reduced multiple fibrosis markers compared to untreated UUO mice. Key fibrotic proteins including alpha-smooth muscle actin, fibronectin, collagen I, and vimentin were all significantly decreased. The drug also reduced transforming growth factor-beta (TGF-β) expression, the master regulator of kidney fibrosis. Mechanistically, artesunate blocked the canonical TGF-β/SMAD pathway by reducing phosphorylated SMAD2/3 proteins and prevented their nuclear translocation.
Crucially, artesunate restored expression of klotho protein, an anti-aging factor that protects against kidney injury and is typically lost in chronic kidney disease. The treatment also suppressed the harmful Wnt/β-catenin pathway by reducing β-catenin accumulation and nuclear translocation. Additionally, artesunate blocked the PI3K/Akt/mTOR pathway, another driver of fibrosis, and reduced cell proliferation in the damaged kidneys.
In human kidney fibroblast cell cultures, artesunate induced ferroptosis—a form of regulated cell death characterized by iron-dependent lipid damage—specifically targeting the cells responsible for excessive scar formation. This selective elimination of harmful fibroblasts represents a novel therapeutic mechanism.
These findings suggest artesunate could become the first effective treatment to delay chronic kidney disease progression and prevent kidney fibrosis development. However, the study was conducted only in mice and cell cultures, requiring human clinical trials to confirm safety and efficacy before clinical application.
Key Findings
- Artesunate significantly reduced key fibrosis markers including alpha-smooth muscle actin, fibronectin, collagen I, and vimentin in UUO mice
- Treatment restored klotho protein expression, which is typically lost in chronic kidney disease and protects against kidney injury
- Artesunate blocked TGF-β/SMAD pathway by reducing phosphorylated SMAD2/3 proteins and preventing nuclear translocation
- The drug suppressed Wnt/β-catenin pathway by reducing β-catenin accumulation and nuclear translocation
- Artesunate inhibited PI3K/Akt/mTOR pathway activation and reduced cell proliferation in damaged kidneys
- In human kidney fibroblasts, artesunate selectively induced ferroptosis, eliminating cells responsible for excessive scarring
- Treatment reduced transforming growth factor-beta expression, the master regulator of kidney fibrosis
Methodology
Researchers used male C57BL/6J mice (6-8 weeks old) in a unilateral ureteral obstruction model, where one ureter was surgically blocked for 10 days to induce kidney fibrosis. Mice received daily intraperitoneal injections of artesunate (100 mg/kg) or vehicle control. The study included sham-operated controls and used multiple analytical techniques including immunoblot analysis, immunohistochemistry, gene expression assays, and ELISA. Human kidney fibroblast cell cultures were used for in vitro validation studies.
Study Limitations
The study was conducted only in mice and human cell cultures, requiring clinical trials to confirm safety and efficacy in humans. The researchers did not report any conflicts of interest, and the study was funded by the Diabetic Kidney Disease Centre. Long-term effects and optimal dosing regimens for kidney disease remain to be determined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.